Publikationen Dr. T. Lutz
Veröffentlichungen und Abstracts
1996
1.
Lutz T, Kamps BS, Brodt HR, Gute P, Staszewski S, Helm EB. Increased survival over subsequent 3-years-periods: the global impact of therapeutic intervention in 908 patients. XI Int Conf AIDS 1996 Jul 7-12; Vancouver, Canada; , 11 (2):99 (abstract no. We.B.3250).
2.
Albrecht H, Sobottka I, Emminger C, Jablonowski H, Just G, Stoehr A, Kubin T, Salzberger B, Lutz T, van Lunzen J. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med. 1996 Feb;120(2):189-98. Review
1998
1.
Lutz T, Stark T, Gute P, Miller V, Guempel H, Staszewski S, Helm E. Long lasting remission of CMV-retinitis without specific CMV-maintenance therapy after initiation of HAART in 4 AIDS patients. 12th World AIDS Conference Geneva, Switzerland; 1998 Jun 28-Jul 3 (poster no. 22268).
2.
Müller A, Miller V, Phillips A, Morgenstern B, Kortenbusch M, Hertogs K, Lutz T, Staszewski S. Virological response in patients switching from AZT/3TC or AZT/ddC to other double NRTI combinations. 12th World AIDS Conf Geneva; 1998 Jun 28-Jul 3 (poster no. 32281).
2000
1.
Miller V, Sabin C, Hertogs K, Larder B, Bloor S, Lutz T, Gute P, Phillips A, Staszewski S. Virological and immunological effects of treatment interruptions in HIV-infected patients with treatment failure. AIDS. 2000 Dec 22;14(18):2857-67
2.
Gute P, Locher L, Carlebach A, Lutz T, Staszewski S, Miller V. Sustained viral suppression with amprenavir plus ritonavir with abacavir/zidovudine/lamivudine in heavily pretreated patients. Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000; abstract P40A. AIDS 2000; 14 (Suppl 4):S28.
2001
1.
Gute P, Locher L, Carlebach A, Lutz T, Miller V, Staszewski S. Salvage Therapie mit Amprenavir plus Ritonavir plus Abacavir bei massiv vorbehandelten Patienten. 8. Deutscher AIDS Kongress; Berlin 4.-7. Juli 2001.
2.
Rickerts V, Haas K, Bickel M, Lutz T, Brodt HR. Laktatazidosen und symptomatische Hyperlaktatämie unter antiretroviraler Therapie. 8. Deutscher AIDS Kongress; Berlin 4.-7. Juli 2001.
3.
Stephan C, Lutz T, Haberl A, Stürmer M, Kurowski M, Staszewski S. Lopinavir-saquinavir without RTI in pre-treated patients with NUC associated resistance or toxicity. 8th European Conference on clinical aspects and treatment of HIV-Infection; Athens 28-31 Oct 2001; abstract LB/P8.
4.
Brodt HR, Lutz T, Rickerts V, Helm EB. Der Teufel und der Belzebub – Opportunistische Erkrankungen und die Folgen von HAART. 8. Deutscher AIDS Kongress; Berlin 4.-7. Juli 2001.
5.
Stephan C, Lutz T, Haberl A, Stürmer M, Kurowski M, Staszewski S. Lopinavir-saquinavir without RTI in pre-treated patients with NUC associated resistance or toxicity. 8th European Conference on clinical aspects and treatment of HIV-Infection; Athens 28-31 Oct 2001; abstract LB/P8.
2002
12.
C. Sabin, B. Dauer, A. N. Phillips, Lutz T, V. Miller, A. Cozzi Lepri, and S. Staszewski. Poorer Immunological Response to HAART in HIV+ Individuals Co-Infected with Hepatitis C Virus. 9th Conference on Retroviruses and Opportunistic Infections; 24 – 28 Feb. 2002; Seattle, WA, USA; abstract 639-M.
13.
Staszewski S, Dauer B, Carlebach A, Gute P, Klauke S, Lutz T, Mösch M. Standardized analysis of response to salvage Therapy in the Frankfurt HIV cohort. 6th International Workshop on HIV Observational databases.; Sintra, Portugal 21-22 March 2002; abstract.
14.
Stephan C , Lutz T, Kurowski M, Gute P, Staszewski S. Lopinavir/Ritonavir versus Ritonavir 100mg boosted Saquinavir plasma levels. 14th International AIDS Congress; Barcelona, Spain 7-12 July 2002; abstract TuPe4561.
15.
Stephan C, von Hentig N, Mösch M, Carlebach A, Kurowski M, Klauke S, Lutz T, Staszewski S. Saquinavir plasma exposure is not decreased in lopinavir/ritonavir co-administration compared to standard ritonavir booster by AUC in steady state. 6th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland 17-21 Nov. 2002; abstract P 176.
2003
1.
Stephan C, von Hentig V, Mösch M, Carleback A, Kurowski M, Klauke S, Lutz T, Staszewski S. Pharmacokinetic comparison of single versus double boosted protease inhibitor regimen: effective saquinavir levels by co-administration with lopinavir/ritonavir. The Second IAS Conference on HIV Pathogenesis and Treatment; Paris, France 13-15 July 2003; abstract 1119. Antiviral Therapy 2003;8:S502.
2.
Von Hentig N. (1), Dauer B. (2), Moesch M. (2), Carlebach A. (2), Lutz T. (3), Kurowski M. (4), Harder S. (1), Staszewski S. - Indinavir Plasma Exposure Is Not Affected By Ritonavir/Lopinavir Co-Administration In A Boosted Double Pnly Therapy Regimen. 9th European Aids Conference (EACS), 1st EACS Resistance & Pharmacology Workshop; Warsaw, Poland 25 – 29 Oct, 2003; abstract F2/4.
2004
1.
Stephan C, von Hentig N, Kourbeti I, Dauer B, Mösch M, Lutz T, Klauke S, Harder S, Kurowski M. Staszewski S. Saquinavir exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18:503-508.
2.
von Hentig NH, Müller A, Haberl A, Lutz T, Knecht G, Kuowski M, Harder S, Staszewski S. The ATSAQ-1 cohort study: Pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor regimen. XV International AIDS Conference; Bangkok 11-16 July 2004; abstract WeOrB1235.
3.
Dauer B, Stuermer M, Nisius G, Mueller A, Kurowski M, Lutz T, Klauke S, Staszewski S. Early Response To A Once-Daily Regimen Consisting Of Boosted Atazanavir Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors In Protease Inhibitor-Experienced Patients. 7th International Congress on Drug Therapy in HIV Infections; Glasgow, Scotland 14-18 Nov 2004; abstract P 25.
4.
Stephan C, Berger AM, Lutz T, Dauer B, Stuermer M, Staszewski S. Tenofovir In Use For HIV in Chronic Hepatitis B Co-infected Individuals. 7th International Congress on Drug Therapy in HIV Infections; Glasgow, Scotland 14-18 Nov 2004; abstract P230.
5.
von Hentig N, Haberl A, Lutz T, Kurowski M, Staszewski S. Pharmacokinetic Interactions of Atazanavir (ATV) and Saquinavir (SQV) in a Ritonavir (RTV) boosted protease inhibitor Therapy Regimen. 7th International Congress on Drug Therapy in HIV Infections; Glasgow, Scotland 14-18 Nov 2004; abstract P276.
6.
Sheldon J, Camino N, Klausen G, Mauss S, Lutz T, Tacke F, Soriano V. Genotypic changes in HBV DNA of HBV/HIV co-infected patients after long-term exposure to tenofovir. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC), October 30 - November 2, 2004, Washington DC
7.
Baumgarten A, Vogel M, Seidel T, Hoffmann M, Mayr C, Theisen A, Lutz T, Rausch M, Jessen H, Schranz D, Fenske S, Mauss S, Spengler S, Rockstroh J. Course and treatment of acute hepatitis C infection in HIV-infected patients: a multicenter prospective trial. 7th International Congress on Drug Therapy in HIV Infections; Glasgow, Scotland 14-18 Nov 2004; abstract 301.
8.
Vogel M, Bieniek B, Jessen H, Schewe CK, Lutz T, Kroidl A, Bogner J, Spenler U, Sauerbruch T, Rockstroh JK . Interferon zur Behandlung der akuten Hepatitis C (HCV-) Infektion bei HIV-koinfizierten Patienten, Abstract P114, 110. Tagung DGIM 17.04.-21.04.2004.
9.
Stephan C, Brodt H-R, Berger A, Lutz T, Mösch M, Lennemann T-S, Stürmer M, Staszewski S. Hemolytic anemia after nucleoside antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient. : AIDS. 2004 Feb 20;18(3):503-8.
2005
1.
Mauss S, Nelson M, Lutz T, Sheldon J, Bruno R, van Bömmel F, Rockstroh J, Wolf E, Stoehr A, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Wunsche T, Jaeger H, Schmutz G. First line combination therapy of chronic hepatitis B with tenofovir plus lamivudin versus sequential therapy with tenofovir monotherapy after lamivudine failure. Abstract 63945, AASLD 2005, San Francisco.
2.
Vogel M, Baumgarten A, Klausen G, Lutz T, Mauss S, Theisen A, Gute P, Rausch M, Schranz D, Bieniek B, Hoffmann C, Trein A, Schewe K, Ummard K, Carganico A, Spengler U, Rockstroh J. Predictive factors in the treatment of acute HCV infections HIV positive individuals – interim analysis in a large german multicenter study. Abstract 63895, AASLD 2005, San Francisco.
3.
Carlebach A, Staszewski S, Dauer B, Khaykin P, Lutz T, HIV Cohort Frankfurt. Favourable tolerability of Double boosted PI without reverse transcriptase inhibitors coadministered with PEG-INF plus Ribavirin in HIV/HCV coinfected patients. 10th European AIDS Conference (EACS); 17-20 Nov 2005; Dublin, Ireland; Abstract PE 13.2/11.
4.
Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S and Soriano V. Selection of hepatitis B virus polymerase mutations in human immunodeficiency virus coinfected patients treated with Tenofovir. Antivir Ther. 2005;10(6):727-34
5.
Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother. 2005 Dec;56(6):1087-93. Epub 2005 Nov 3
6.
Bickel M, Zangos S, Jacobi V, Lutz T, Goebel F, Staszewski S, Klauke S. Effects of Recombinant Human Growth Hormone (r-hGH) on Fat Depletion and Plasma Lipids in HIV-1 Infected Patients With Lipodystrophy - A Randomised, Open-label Study. 12th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, USA 22-25 Feb 2005; abstract 855.
7.
Bickel M, Zangos S, Jacobi V, Lutz T, Goebel F, Staszewski S, Klauke S. Effects of Recombinant Human Growth Hormone (r-hGH) on Fat Depletion and Plasma Lipids in HIV-1 Infected Patients With Lipodystrophy - A Randomised, Open-label Study. 10. Deutscher und 16. Österreichischer AIDS-Kongress; Vienna, Austria 1-4 June 2005; abstract P225.
8.
Khaykin P, Carlebach A, Klauke S, Lutz T, Mösch M, Staszewski S. Efavirenz to nevirapine switch therapy: Evaluation of consequences. 10th European AIDS Conference (EACS); 17-20 Nov 2005; Dublin, Ireland; Abstract PE 9.8/7.
9.
von Hentig N, Haberl A, Mueller A, Lutz T, Klauke S, Kurowski M, Harder S, Staszewski S. Effect of atazanavir (ATV) co-administration on the pharmacokinetics (PK) of either saquinavir (SQV), lopinavir (LPV) or fosamprenavir (FosAPV) when combined in ritonavir (RTV)-boosted double protease inhibitor (PI) therapy regimens. 10th European AIDS Conference (EACS); 17-20 Nov 2005; Dublin, Ireland; Abstract PS 6/5.
2006
1.
von Hentig N, Mueller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski S, Harder S. Steady-state pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. Eur J Med Res. 2006 Jun 30;11(6):236-44
2.
Bickel M, Zangos S, Jacobi V, Lutz T, Knecht G, Goebel F, Staszewski S, Klauke S. A randomized open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. HIV Med. 2006 Sep;7(6):397-403
3.
Carlebach A, Staszewski S, Dauer B, Khaykin P, Knecht G, Lutz T. Boosted Double PI Without Reverse Transcriptase Inhibitors Coadministered With Peg-Inf Plus Ribavirin In 10 HIV/HCV Coinfected Patients: 48 Week Results. ICAAC (2006)
4.
Ahlenstiehl G, Vogel M, Klausen G, Lutz T, Schürmann D, Carlebach A, Schmidt W, Dupke S, Buggisch P, Rieke A, Fenske S, John C, Gölz J, Kern P, Klinker H, Staszewski S, Rockstroh JK for the German Hepatitis Group. The influence of nucleoside free HAART on the treatment of chronic hepatitis C with pegylated interferon / ribavirin combination treatment. Poster, ICAAC (2006)
5.
Vogel M, Nattermann J, Baumgarten A, Klausen G, Lutz T, Mauss S, Mayr C, Hintsche B, Schranz D, Bieniek B, Stellbrink HJ, Schuler C, Schewe K, Ummard K, Carganico A, Rockstroh JKfor the German Hepatitis Group Treatment of sexually transmitted acute HCV-infection in HIV-positive individuals. Poster, ICAAC (2006)
5.
Lutz Tand Staszewski S. A patient reluctant to take antiretroviral therapy. In
6.
Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, Jessen H, Boesecke C, Rausch M, Lutz T, Fenske F, Schranz D, Kuemmerle T, Schuler C Theisen A, Mayr C, Seidel T, Rockstroh J. Pegylated interferon in the treatment of sexually transmitted acute hepatitis C in HIV infected individuals. Antiviral Therapy (2006).
7.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Efficacy and tolerability of Peginterferon alfa 2A (40 KD) and Ribavirin in GT-1 patients with chronic hepatitis C in Germany – a contribution to health care research. Poster, EASL 2006, Wien
8.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Efficacy and safety of Peginterferon alfa 2A (40 KD) and Ribavirin in GT-2/3 patients with chronic hepatitis C in a real world setting. Poster, EASL 2006, Wien
9.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Ensuring quality in the treatment of chronic hepatitis C (CHC): A comparison of treatment under everyday conditions with existing recomendations in Germany. Poster, EASL 2006, Wien
10.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Efficacy and safety of Peginterferon alfa 2A (40 KD) and Ribavirin [RBV] 1000/1200 mg/d in GT-1 patients with chronic hepatitis C and “normal” ALT levels. Poster, EASL 2006, Wien
11.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Efficacy and tolerability of Peginterferon alfa 2A (40 KD) and Ribavirin in patients with or without druguse. DDW 2006, Abstract
12.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Efficacy and tolerability of Peginterferon alfa 2A (40 KD) and Ribavirin in GT-1 patients with chronic hepatitis C in Germany – a contribution to health care research. DDW 2006, Abstract
13.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Efficacy and safety of Peginterferon alfa 2A (40 KD) and Ribavirin in GT-2/3 patients with chronic hepatitis C in a real world setting. DDW 2006, Abstract
14.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D. Predictive factors in treatment of chronic hepatitis C (CHC) patients with peginterferon alfa 2a (40 KD) and ribavirin. DDW 2006, Abstract
15.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz TBokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D and the bng-Hepatitis study group. Ensuring quality in the treatment of chronic hepatitis C (CHC): a comparison of treatment under everyday conditions with existing recomendations in Germany. IASL 2006. Abstract
16.
Zehnter E, Mauss S, John C, Heyne R, Moeller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hueppe D and the bng-Hepatitis study group. Efficacy and tolerability of peginterferon alfa-2a (40 KD) and ribavirin in GT-4 patients with chronic hepatitis C in Germany – A contribution to health care research. IASL 2006. Abstract
17.
Knechten H, Lutz T, Knecht G, Stephan C, Carganico A, Gläßel F, Jaeger H, Stoehr A, Tappe A, Wellmann E: The Rainbow Cohort: First results from Germany with the new saquinavir 500 mg formulation; 44th Annual Meeting of the IDSA, Toronto, Canada, October 12-15, 2006
18.
Knechten H, Lutz T, Knecht G, Haberl A, Carganico A, Glaessel F, Jaeger H, Tappe A, Wellmann E, Steinmueller J: The Rainbow-Cohort: successful initiation with or switch to the new saquinavir 500 mg formulation - first results from Germany; 8th International Congress on Drug Therapy in HIV-Infection, Abstract No P58, Glasgow, UK, 2006
19.
Carlebach A, Staszewski S, Dauer B, Khaykin P, Lutz T. Boosted Double PI Without Reverse Transcriptase Inhibitors Coadministered With Peg-Inf Plus Ribavirin In 10 HIV/HCV Coinfected Patients: 24 Week Results. Abstract 33, 2nd International Workshop on HIV & Hepatitis Co-infection Reviews in Antiviral Therapy (2006), 1: 37-38
20.
Vogel M, Baumgarten A, Klausen G, Lutz T, Wiesel W, Cordes C, Hoffmann C, Schewe K, Spengler U, Rockstroh J for the German Hepatitis Group Treatment of sexually transmitted acute HCV-infection in HIV-positive individuals. Pegylated interferon in the treatment of acute HCV-infection in HIV-positive individuals – Interim analysis of a large German multicenter study. Abstract 25, 2nd International Workshop on HIV & Hepatitis Co-infection, Reviews in Antiviral Therapy (2006), 1: 33-34
21.
Mauss S, Nelson M, Lutz T, Sheldon J, Bruno R, van Boemmel F, Rockstroh J, Stoehr A, Wolf E, Benhamou Y, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Wunsche T, Jaeger H, Schmutz G. First line combination therapy of chronic hepatitis B with tenofovir plus lamivudin versus sequential therapy with tenofovir monotherapy after lamivudine failure. Abstract 42 2nd International Workshop on HIV & Hepatitis Co-infection, Reviews in Antiviral Therapy (2006) 1, 42.
22.
Mauss S, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Pollock K, Berg T, Carlebach A, Schwarze-Zander C, Wunsche T, Jaeger H, Schmutz G. First line therapy of chronic hepatitis B with tenofovir and lamivudine versus sequential therapy with tenofovir after lamivudine failure. Hepatology 2006.
23.
Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schurmann D, Jaeger H, Mauss S (2006) Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS. 2006 Oct 3;20(15):1951-1954.
24.
Zehnter E, Mauss S, John C, Heyne R, Möller B, Lutz T, Bokemeyer B, Kihn R, Moog G, Alshuth U, Hüppe D (2006) Better prediction of SVR in patients with HCV genotype 1 (G1) with peg-interferon alpha 2a (Pegasys) plus Ribavirin: Improving with differentiation between low (LVL) and high baseline viral load (HVL). ASSLD 2006, Boston, Poster
2007
1.
Zehnter E, Mauss S, Boeker H, Lutz T, Racky S, Schmidt W, Ulrich R, Sbrijer I, Heyne R, Schober A, John C, Hey KH, Bokemeyer B, Kalinowski B, Moeller B, Pape S, Alshuth U, Hueppe D (2007) Potential relevance of rapid viral response for SVR and optimation of treatment of hepatitis C (CHC) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV). EASL 2007, Poster
2.
Zehnter E, Mauss S, Boeker H, Lutz T, Racky S, Schmidt W, Ulrich R, Sbrijer I, Heyne R, Schober A, John C, Hey KH, Bokemeyer B, Kalinowski B, Moeller B, Pape S, Alshuth U, Hueppe D (2007). The role of glomerular filtration rate (GFR) for treatment with Peginterferon alfa 2a (PEG) and Ribavirin (RBV) in patients with chronic hepatitis C (CHC). EASL 2007, Poster
3.
van Lunzen J, Fätkenheuer G, Lutz T, Klauke S, Mauss S, Knechten H, Braun P, Mertenskoetter T, Gallo L & Ranneberg B. Efficacy and Tolerability of TDF/FTC-containing First Line HAART in Clinical Practice – 24 Week Data from a German Outpatient Cohort. DÖÄK 2007, Frankfurt, Poster
4.
Knechten H, Carganico A, Glaessel F, Jaeger H, Knecht G, Koeppe S, Lutz T, Mayr C, Mosthaf F, Schewe K, Schuler C, Stephan C, Wolf E, Steinmueller J, Tappe A, Waesle B, Wellmann E: The Rainbow Cohort: Saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients initiating treatment with saquinavir 500mg film-coated tablets - 24 week interim results from Germany; Deutsch-Österreichischer AIDS-Kongress, Frankfurt am Main, 2007, Poster
5.
Meyer U, Zehnter E, Mauss S, Boeker K, Lutz T, Racky S, Schmidt W, Ullrich R, Sbrijer I, Heyne R, Schober A, John C, Hey KH, Bokemeyer B, Kallinowski B, Moeller B, Pape S, Alshuth U, Hueppe D. Treatment of chronic hepatitis C (CHC) with peginterferon alfa-2a (40kd) (PEG) and ribavirin (RBV) in patients older than 60 years. DDW 2007, Poster
6.
Zehnter E, Mauss S, Boeker K, Lutz T, Racky S, Schmidt W, Ullrich R, Sbrijer I, Heyne R, Schober A, John C, Hey KH, Bokemeyer B, Kallinowski B, Moeller B, Pape S, Alshuth U, Hueppe D. Differences between genotype 1 patients with SVR or relapse after treatment for chronic hepatitis C (CHC) with peginterferon alfa-2a (40kd) (PEG) and ribavirin (RBV). DDW 2007, Poster
7.
Bickel M, Zangos S, Lutz T, Eisen J, Knecht G, Goebel F, Crespi C, Jacobi V, Staszewski S, Klauke S. Long term effect on body composition and metabolic parameters after treatment with recombinant human Growth Hormon (r-hGH) in HIV-1 infected patients with lipodystrophy. Scand J Infect Dis 2007 Jul 6; 1-4
8.
Rockstroh JK, Ahlenstiehl G, Vogel M, Klausen G, Lutz T, Schürmann D, Carlebach A, Mayr C , Carganico A, Buggisch P, Klinker H, John C, Gölz J, Staszewski S for the German Hepatitis Group. The influence of nucleoside free HAART on the treatment of chronic hepatitis C with pegylated interferon / ribavirin combination treatment. Poster. EASL 2007
9.
Nattermann J, Vogel M, Berg T, Danta M, Baumgarten A, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewes K, Bienek B, Haerter G, Sauerbruch T, Rockstroh J, Spengler U, for the Kompetenznetz HIV/AIDS. Effect of the il-6 C174G gene polymorphismus on treatment of acute and chronic hepatitis C in HIV co-infetcted Patients. Hepatology
10.
Khaykin P, Vogel M, Voigt E, Rockstroh J, Carlebach A, Lutz T, Staszewski S. Impact of different ART regimens on efficacy and safety of standard HCV treatment in HIV/HCV co-infected patients. IAS, Sydney, Australia, July 2007, Poster MOPEB056
11.
Khaykin P, Vogel M, Voigt E, Carlebach A, Lutz T, Babacan E , Rockstroh J, Staszewski S. Different ART regimens and efficacy of HCV treatment in HIV patients co-infected with HCV genotype 1. EACS, Madrid, October 2007, Poster
12.
Bickel M, Eisen J, Stephan C, Crespi CM, Lutz T, Klauke S, Vogl TJ, Jacobi V, Yang OO, Staszewski S and Zangos S. A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantifcation of HIV-1-associated lipodystrophy. HIV Med. 2007; 8:413-8.
13.
Bickel M, Zangos S, Lutz T, Eisen J, Knecht G, Goebel F, Crespi CM, Jacobi V, Staszewski S and Klauke S. Long term effect on body composition and metabolic parameters after treatment with recombinant human growth hormon (r-hGH) in HIV-1 infected patients with lipodystrophy. Scandinavian Journal of Infectious diseases 2007, 1-4
14.
van Lunzen J, Fätkenheuer G, Lutz T, Klauke S, Mauss S, Knechten H, Braun P, Gallo L, Ranneberg B. Efficacy and tolerability of TDF/FTC-containing first line HAART in clinical practice – 48 week data from the german outpatient cohort. Poster P7.3/06, 11th EACS, 24.-27. October, Madrid, Spanien
15.
von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol. 2007 Oct;63(10):935-40.
2008
1.
Mauss S, Zehnter E, Hueppe D, Kaiser K, Boeker K, Lutz T, Heyne R, John C, Moog G, Schober A, Pfaff R, Zipf A, Racky S, Lohmeyer L, Bokemeyer B, Kallinowski B, Witthoeft T, Alshuth U. The role of cholesterol on sustained virological response (SVR) in the treatment of genotyp-1 infected hepatitis C (CHC) patients with peginterferon alfa 2a (PEG) an Ribavirin (RBV). Poster EASL 2008, Milan
2.
Zehnter E, Mauss S, Kaiser S, Boeker K, Lutz T, Heyne R, John C, Moog G, Schober A, Pfaff R, Zipf A, Racky A, Lohmeyer J, Bokemeyer B, Kallinowski B. Witthoeft T, Alshuth U, D. Hueppe D. Efficacy and tolerability of Peginterferon alfa-2a (40KD) and ribavirin in genotype 4 patients with chronic hepatitis C (CHC) under real life conditions. Poster EASL, 2008, Milan
3.
van Lunzen J, Fätkenheuer G, Lutz T, Klauke S, Mauss S, Knechten H, Braun P, Gallo L, Ranneberg B. Efficacy and safety of TDF/FTC-containing first line HAART in clinical practice – 48 week data from the german outpatient cohort. Poster , IAS, Mexico City, Mexico
